Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Baylor College of Medicine
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06198296CT.gov Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatoblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 21.15.gpc3-car t cells (this asset) | Baylor College of Medicine | P1 | CC · 43 |
| Etoposide | Children's Oncology Group | P3 | BB |
| (+)-Vincristine | University of Birmingham | P3 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | BB |
| Carboplatin | Children's Oncology Group | P3 | BB |
| Gm-Csf | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | B |
| Oxaliplatin | Children's Oncology Group | P3 | B |
| Irinotecan | Children's Oncology Group | P3 | B |
| Vincristine Sulfate | Children's Oncology Group | P3 | B |
+42 more in the Hepatoblastoma cohort
Other indications for 21.15.gpc3-car t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atypical Teratoid Rhabdoid Tumor | — | P1 | CC · 43 |
| Wilms Tumor | — | P1 | CC · 43 |
| Rhabdoid Tumor | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 21.15.gpc3-car t cells in Hepatoblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2115gpc3-car-t-cells-hepatoblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →